2020 - NANETS https://nanets.net/abstracts-archive/2020?format=html Thu, 20 May 2021 14:33:01 -0400 en-GB hourly 1 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and or Unresectable Pheochromocytoma and Paraganglioma (1) (4) https://nanets.net/abstracts-archive/2020/1555-the-north-american-neuroendocrine-tumor-society-consensus-guidelines-for-surveillance-and-management-of-metastatic-and-or-unresectable-pheochromocytoma-and-paraganglioma-1-4?format=html The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and or Unresectable Pheochromocytoma and Paraganglioma (1) (4) https://nanets.net/abstracts-archive/2020/1555-the-north-american-neuroendocrine-tumor-society-consensus-guidelines-for-surveillance-and-management-of-metastatic-and-or-unresectable-pheochromocytoma-and-paraganglioma-1-4?format=html wertherm@adgcommunications.com (Maureen Werther) 2020 Thu, 20 May 2021 14:33:01 -0400 C40 - Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience https://nanets.net/abstracts-archive/2020/1454-c40-renal-and-hepatotoxicity-of-peptide-receptor-radionuclide-therapy-prrt-a-single-institution-experience?format=html C40 - Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 201

]]> https://nanets.net/abstracts-archive/2020/1454-c40-renal-and-hepatotoxicity-of-peptide-receptor-radionuclide-therapy-prrt-a-single-institution-experience?format=html H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 201

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 14:18:40 -0400 C39 - Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience https://nanets.net/abstracts-archive/2020/1453-c39-hematotoxicity-of-peptide-receptor-radionuclide-therapy-prrt-a-single-institution-experience?format=html C39 - Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience H. Duan, V. Ferri, P. Kunz, G. Davidzon, F. Moradi, J. Nguyen, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 199

]]> https://nanets.net/abstracts-archive/2020/1453-c39-hematotoxicity-of-peptide-receptor-radionuclide-therapy-prrt-a-single-institution-experience?format=html H. Duan, V. Ferri, P. Kunz, G. Davidzon, F. Moradi, J. Nguyen, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 199

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 14:17:37 -0400 C38 - Hepatotoxicity in Previously Treated Y-90 Metastatic Neuroendocrine Cancer Patients after PRRT: Single Institution Experience https://nanets.net/abstracts-archive/2020/1452-c38-hepatotoxicity-in-previously-treated-y-90-metastatic-neuroendocrine-cancer-patients-after-prrt-single-institution-experience?format=html C38 - Hepatotoxicity in Previously Treated Y-90 Metastatic Neuroendocrine Cancer Patients after PRRT: Single Institution Experience Y.L. Wong, J. Thomas, A. Shreenivas

ABSTRACT ID: 197

]]> https://nanets.net/abstracts-archive/2020/1452-c38-hepatotoxicity-in-previously-treated-y-90-metastatic-neuroendocrine-cancer-patients-after-prrt-single-institution-experience?format=html Y.L. Wong, J. Thomas, A. Shreenivas

ABSTRACT ID: 197

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 14:16:10 -0400 C37 - Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET) https://nanets.net/abstracts-archive/2020/1451-c37-single-institution-experience-with-peptide-receptor-radionuclide-therapy-prrt-in-neuroendocrine-tumors-net?format=html C37 - Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET) H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 194

]]> https://nanets.net/abstracts-archive/2020/1451-c37-single-institution-experience-with-peptide-receptor-radionuclide-therapy-prrt-in-neuroendocrine-tumors-net?format=html H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 194

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 14:15:13 -0400 C36 - 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A Potential Breakthrough in Treatment of Metastatic SSTR Expressing NET https://nanets.net/abstracts-archive/2020/1450-c36-212pb-alphamedixtm-targeted-alpha-therapy-tat-a-potential-breakthrough-in-treatment-of-metastatic-sstr-expressing-net?format=html C36 - 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A Potential Breakthrough in Treatment of Metastatic SSTR Expressing NET E. Delpassand, I. Tworowska, J. Torgue, J. Hurt, R. Nuñez, R. Esfandiari

ABSTRACT ID: 193

]]> https://nanets.net/abstracts-archive/2020/1450-c36-212pb-alphamedixtm-targeted-alpha-therapy-tat-a-potential-breakthrough-in-treatment-of-metastatic-sstr-expressing-net?format=html E. Delpassand, I. Tworowska, J. Torgue, J. Hurt, R. Nuñez, R. Esfandiari

ABSTRACT ID: 193

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 14:14:05 -0400 C35 - Real-World Analysis of Safety and Tolerance of Repeat Peptide Receptor Radionuclide Therapy https://nanets.net/abstracts-archive/2020/1449-c35-real-world-analysis-of-safety-and-tolerance-of-repeat-peptide-receptor-radionuclide-therapy?format=html C35 - Real-World Analysis of Safety and Tolerance of Repeat Peptide Receptor Radionuclide Therapy J. Chau, H. Bakeri, N. Yu, Y. Menda, J. Dillon, C. Chandrasekharan

ABSTRACT ID: 192

]]> https://nanets.net/abstracts-archive/2020/1449-c35-real-world-analysis-of-safety-and-tolerance-of-repeat-peptide-receptor-radionuclide-therapy?format=html J. Chau, H. Bakeri, N. Yu, Y. Menda, J. Dillon, C. Chandrasekharan

ABSTRACT ID: 192

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 14:12:36 -0400 C34 - An Initial Experience in Establishing a Theranostic Precision Medicine PRRT Targeted Radiotherapy Program for the Treatment of GEP-NETs with Lu-177 Dotatate (Lutathera) in a Major Academic University Hospital https://nanets.net/abstracts-archive/2020/1448-c34-an-initial-experience-in-establishing-a-theranostic-precision-medicine-prrt-targeted-radiotherapy-program-for-the-treatment-of-gep-nets-with-lu-177-dotatate-lutathera-in-a-major-academic-university-hospital?format=html C34 - An Initial Experience in Establishing a Theranostic Precision Medicine PRRT Targeted Radiotherapy Program for the Treatment of GEP-NETs with Lu-177 Dotatate (Lutathera) in a Major Academic University Hospital P. Wojtylak, A. Mohamed, N. Avril, A. Kardan

ABSTRACT ID: 173

]]> https://nanets.net/abstracts-archive/2020/1448-c34-an-initial-experience-in-establishing-a-theranostic-precision-medicine-prrt-targeted-radiotherapy-program-for-the-treatment-of-gep-nets-with-lu-177-dotatate-lutathera-in-a-major-academic-university-hospital?format=html P. Wojtylak, A. Mohamed, N. Avril, A. Kardan

ABSTRACT ID: 173

]]> emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 09 Oct 2020 13:54:58 -0400 C55 - The Proliferative Indices of the Primary Ileal Well-Differentiated Neuroendocrine Tumors, Corresponding Lymph Nodes/ Mesenteric Deposits, and Distant Metastatic Sites Show Poor Correlation https://nanets.net/abstracts-archive/2020/1447-c55-the-proliferative-indices-of-the-primary-ileal-well-differentiated-neuroendocrine-tumors-corresponding-lymph-nodes-mesenteric-deposits-and-distant-metastatic-sites-show-poor-correlation?format=html C55 - The Proliferative Indices of the Primary Ileal Well-Differentiated Neuroendocrine Tumors, Corresponding Lymph Nodes/ Mesenteric Deposits, and Distant Metastatic Sites Show Poor Correlation https://nanets.net/abstracts-archive/2020/1447-c55-the-proliferative-indices-of-the-primary-ileal-well-differentiated-neuroendocrine-tumors-corresponding-lymph-nodes-mesenteric-deposits-and-distant-metastatic-sites-show-poor-correlation?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 13:23:52 -0400 C54 - Survival After Resection of Poorly Differentiated Gastroenteropancreatic Neuroendocrine Neoplasm: Association of Nodal Involvement and Survival https://nanets.net/abstracts-archive/2020/1446-c54-survival-after-resection-of-poorly-differentiated-gastroenteropancreatic-neuroendocrine-neoplasm-association-of-nodal-involvement-and-survival?format=html C54 - Survival After Resection of Poorly Differentiated Gastroenteropancreatic Neuroendocrine Neoplasm: Association of Nodal Involvement and Survival https://nanets.net/abstracts-archive/2020/1446-c54-survival-after-resection-of-poorly-differentiated-gastroenteropancreatic-neuroendocrine-neoplasm-association-of-nodal-involvement-and-survival?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 13:20:43 -0400 C53 - Well-Differentiated Rectal Neuroendocrine Tumors: Analysis of Histology, Including INSM1 Expression, and Biologic Behavior, Involving a Large Cohort of 94 Cases https://nanets.net/abstracts-archive/2020/1445-c53-well-differentiated-rectal-neuroendocrine-tumors-analysis-of-histology-including-insm1-expression-and-biologic-behavior-involving-a-large-cohort-of-94-cases?format=html C53 - Well-Differentiated Rectal Neuroendocrine Tumors: Analysis of Histology, Including INSM1 Expression, and Biologic Behavior, Involving a Large Cohort of 94 Cases https://nanets.net/abstracts-archive/2020/1445-c53-well-differentiated-rectal-neuroendocrine-tumors-analysis-of-histology-including-insm1-expression-and-biologic-behavior-involving-a-large-cohort-of-94-cases?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 13:18:59 -0400 C52 - Upfront Interventional Treatments Prior to Liver-progression for Small Bowel Neuroendocrine Liver Metastasis https://nanets.net/abstracts-archive/2020/1444-c52-upfront-interventional-treatments-prior-to-liver-progression-for-small-bowel-neuroendocrine-liver-metastasis?format=html C52 - Upfront Interventional Treatments Prior to Liver-progression for Small Bowel Neuroendocrine Liver Metastasis https://nanets.net/abstracts-archive/2020/1444-c52-upfront-interventional-treatments-prior-to-liver-progression-for-small-bowel-neuroendocrine-liver-metastasis?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 13:18:03 -0400 C51 - A Novel Stratification of Mesenteric Mass Involvement as a Predictor of Challenging Mesenteric Lymph Node Dissection by Minimally Invasive Approach for Ileal Neuroendocrine Tumors https://nanets.net/abstracts-archive/2020/1443-c51-a-novel-stratification-of-mesenteric-mass-involvement-as-a-predictor-of-challenging-mesenteric-lymph-node-dissection-by-minimally-invasive-approach-for-ileal-neuroendocrine-tumors?format=html C51 - A Novel Stratification of Mesenteric Mass Involvement as a Predictor of Challenging Mesenteric Lymph Node Dissection by Minimally Invasive Approach for Ileal Neuroendocrine Tumors https://nanets.net/abstracts-archive/2020/1443-c51-a-novel-stratification-of-mesenteric-mass-involvement-as-a-predictor-of-challenging-mesenteric-lymph-node-dissection-by-minimally-invasive-approach-for-ileal-neuroendocrine-tumors?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 13:16:41 -0400 C50 - Socioeconomic Disparities in Midgut Neuroendocrine Tumors (MNETs): An NCDB Analysis https://nanets.net/abstracts-archive/2020/1442-c50-socioeconomic-disparities-in-midgut-neuroendocrine-tumors-mnets-an-ncdb-analysis?format=html C50 - Socioeconomic Disparities in Midgut Neuroendocrine Tumors (MNETs): An NCDB Analysis https://nanets.net/abstracts-archive/2020/1442-c50-socioeconomic-disparities-in-midgut-neuroendocrine-tumors-mnets-an-ncdb-analysis?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:55:21 -0400 C49 - Pattern of Disease Recurrence and Treatment after Surgery for Nonfunctioning Well- Differentiated Pancreatic Neuroendocrine Tumors (NF-PanNET) https://nanets.net/abstracts-archive/2020/1441-c49-pattern-of-disease-recurrence-and-treatment-after-surgery-for-nonfunctioning-well-differentiated-pancreatic-neuroendocrine-tumors-nf-pannet?format=html C49 - Pattern of Disease Recurrence and Treatment after Surgery for Nonfunctioning Well- Differentiated Pancreatic Neuroendocrine Tumors (NF-PanNET) https://nanets.net/abstracts-archive/2020/1441-c49-pattern-of-disease-recurrence-and-treatment-after-surgery-for-nonfunctioning-well-differentiated-pancreatic-neuroendocrine-tumors-nf-pannet?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:54:18 -0400 C48 - Metabolic Changes in Pheochromocytoma and Paraganglioma: Correlation Between Plasma Hormone Levels, Weight and Diabetes https://nanets.net/abstracts-archive/2020/1440-c48-metabolic-changes-in-pheochromocytoma-and-paraganglioma-correlation-between-plasma-hormone-levels-weight-and-diabetes?format=html C48 - Metabolic Changes in Pheochromocytoma and Paraganglioma: Correlation Between Plasma Hormone Levels, Weight and Diabetes https://nanets.net/abstracts-archive/2020/1440-c48-metabolic-changes-in-pheochromocytoma-and-paraganglioma-correlation-between-plasma-hormone-levels-weight-and-diabetes?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:52:22 -0400 C47 - Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems https://nanets.net/abstracts-archive/2020/1439-c47-predicting-metastatic-potential-in-pheochromocytoma-and-paraganglioma-a-comparison-of-pass-and-gapp-scoring-systems?format=html C47 - Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems https://nanets.net/abstracts-archive/2020/1439-c47-predicting-metastatic-potential-in-pheochromocytoma-and-paraganglioma-a-comparison-of-pass-and-gapp-scoring-systems?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:50:19 -0400 C46 - Symptom and Quality Of Life Impairments in Cushing’s Disease Before and After Endoscopic Transsphenoidal Surgery https://nanets.net/abstracts-archive/2020/1438-c46-symptom-and-quality-of-life-impairments-in-cushing-s-disease-before-and-after-endoscopic-transsphenoidal-surgery?format=html C46 - Symptom and Quality Of Life Impairments in Cushing’s Disease Before and After Endoscopic Transsphenoidal Surgery https://nanets.net/abstracts-archive/2020/1438-c46-symptom-and-quality-of-life-impairments-in-cushing-s-disease-before-and-after-endoscopic-transsphenoidal-surgery?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:49:05 -0400 C45 - It’s Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors https://nanets.net/abstracts-archive/2020/1437-c45-it-s-time-to-rethink-biomarkers-for-surveillance-of-small-bowel-neuroendocrine-tumors?format=html C45 - It’s Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors https://nanets.net/abstracts-archive/2020/1437-c45-it-s-time-to-rethink-biomarkers-for-surveillance-of-small-bowel-neuroendocrine-tumors?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:33:05 -0400 C44 - ISL-1 Expression is a Prognostic Marker in Patients With Well- Differentiated Pancreatic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2020/1436-c44-isl-1-expression-is-a-prognostic-marker-in-patients-with-well-differentiated-pancreatic-neuroendocrine-tumors?format=html C44 - ISL-1 Expression is a Prognostic Marker in Patients With Well- Differentiated Pancreatic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2020/1436-c44-isl-1-expression-is-a-prognostic-marker-in-patients-with-well-differentiated-pancreatic-neuroendocrine-tumors?format=html emilyv@adgcommunications.com (Emily Van De Loo) 2020 Fri, 02 Oct 2020 12:27:38 -0400